Expansion of tumor infiltrating lymphocytes (TIL) from bladder cancer

Expansion of tumor infiltrating lymphocytes (TIL) from bladder cancer

Advanced bladder cancer patients have limited therapeutic options resulting in a median overall survival (OS) between 12 and 15 months. Adoptive cell therapy (ACT) using tumor infiltrating lymphocytes (TIL) has been used successfully in treating patients with metastatic melanoma, resulting in a medi...

Full description

Bibliographic Details
Main Authors: Michael Poch, MacLean Hall, Autumn Joerger, Krithika Kodumudi, Matthew Beatty, Pasquale P. Innamarato, Brittany L. Bunch, Mayer N. Fishman, Jingsong Zhang, Wade J. Sexton, Julio M. Pow-Sang, Scott M. Gilbert, Philippe E. Spiess, Jasreman Dhillon, Linda Kelley, John Mullinax, Amod A Sarnaik, Shari Pilon-Thomas
Format: Article
Language:English
Published: Taylor & Francis Group 2018-09-01
Series:OncoImmunology
Subjects:
t cells
bladder cancer
immunotherapy
tumor-infiltrating lymphocytes
4-1bb
Online Access:http://dx.doi.org/10.1080/2162402X.2018.1476816

Internet

http://dx.doi.org/10.1080/2162402X.2018.1476816

Similar Items